Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02446405 |
Recruitment Status :
Active, not recruiting
First Posted : May 18, 2015
Last Update Posted : November 30, 2022
|
Sponsor:
University of Sydney
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Cancer Trials Ireland
Canadian Cancer Trials Group
Information provided by (Responsible Party):
University of Sydney
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | September 2023 |
Estimated Study Completion Date : | December 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):